In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Adaptive Biotechnologies Corp’s stock clocked out at $12.85, down -1.31% from its previous closing price of $13.02. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 1.37 million shares were traded. ADPT stock price reached its highest trading level at $13.205 during the session, while it also had its lowest trading level at $12.525.
Ratios:
To gain a deeper understanding of ADPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.21 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on June 18, 2025, initiated with a Buy rating and assigned the stock a target price of $15.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 16 ’25 when PISKEL KYLE sold 1,929 shares for $8.89 per share. The transaction valued at 17,149 led to the insider holds 277,396 shares of the business.
ROBINS HARLAN S sold 68,412 shares of ADPT for $502,828 on May 01 ’25. The Chief Scientific Officer now owns 1,279,524 shares after completing the transaction at $7.35 per share. On May 01 ’25, another insider, Harlan Robins, who serves as the Officer of the company, bought 68,412 shares for $7.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 1956720896 and an Enterprise Value of 1976600832. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.53 while its Price-to-Book (P/B) ratio in mrq is 10.88. Its current Enterprise Value per Revenue stands at 9.632 whereas that against EBITDA is -19.221.
Stock Price History:
The Beta on a monthly basis for ADPT is 2.05, which has changed by 2.0164318 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, ADPT has reached a high of $13.52, while it has fallen to a 52-week low of $3.98. The 50-Day Moving Average of the stock is 8.83%, while the 200-Day Moving Average is calculated to be 45.84%.
Shares Statistics:
It appears that ADPT traded 2.05M shares on average per day over the past three months and 1795150 shares per day over the past ten days. A total of 152.23M shares are outstanding, with a floating share count of 145.25M. Insiders hold about 4.61% of the company’s shares, while institutions hold 95.05% stake in the company. Shares short for ADPT as of 1755216000 were 8945230 with a Short Ratio of 4.36, compared to 1752537600 on 9686697. Therefore, it implies a Short% of Shares Outstanding of 8945230 and a Short% of Float of 7.5200000000000005.
Earnings Estimates
Investors are keenly observing as 6.0 analysts analyze and rate the current performance of Adaptive Biotechnologies Corp (ADPT) in the stock market.The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.1 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.56 and -$0.8 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.56, with 6.0 analysts recommending between -$0.42 and -$0.66.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $58.91M. It ranges from a high estimate of $71.8M to a low estimate of $54.23M. As of the current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $46.44MFor the next quarter, 6 analysts are estimating revenue of $63.14M. There is a high estimate of $73M for the next quarter, whereas the lowest estimate is $57.6M.
A total of 7 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $256.09M, while the lowest revenue estimate was $224.1M, resulting in an average revenue estimate of $232.92M. In the same quarter a year ago, actual revenue was $178.96MBased on 7 analysts’ estimates, the company’s revenue will be $269.74M in the next fiscal year. The high estimate is $279.6M and the low estimate is $252.48M.
